Cliquez ici pour connaître notre offre FCPI 2014

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


Symetis

Symetis, set up in January 2001, as a spin-off from the University of Zurich, is a a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems.

The company’s lead product, Acurate TA™, based on proprietary geometry and delivery technology, is currently in clinical trials and is well positioned to target the estimated $2 billion TAVI market. Acurate TA™ is on track to obtain CE market approval in 2011. In parallel, Symetis is conducting pre-clinical validation of Acurate TF™, a trans-femoral TAVI solution based on similar design principles, scheduled to enter clinical trials in 2011.

Truffle Capital first invested in Symetis in 2004 and is Symetis’ first shareholder.

Truffle Capital board member: Dr. Philippe Pouletty